Immune-Mediated Toxic Epidermal Necrolysis

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Immune checkpoint inhibitors, including programmed death receptor 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors, represent advanced melanoma treatments.
• PD-1 inhibitors are associated with multi-system adverse reactions, with dermatological events ranging from mild pruritus to severe toxic epidermal necrolysis.

Observation:

• This report details a fatal case of toxic epidermal necrolysis (TEN) occurring secondary to nivolumab therapy.
• The patient's outcome highlights the potential severity of immune checkpoint inhibitor-related dermatologic toxicity.

Findings:

• Toxic epidermal necrolysis is a rare but life-threatening adverse event associated with PD-1 inhibitor therapy.
• Early recognition and management of dermatological complications are crucial for patient outcomes.

Implications:

• Checkpoint inhibitors are increasingly used in various malignancies, necessitating ongoing vigilance regarding their safety profile.
• Physicians must be aware of the spectrum of dermatological toxicities and the risk of opportunistic infections or sepsis in immunocompromised patients or those on combination therapy.